DRUGS TARGETED FOR UPGRADE

Pro-Pharmaceuticals is working to upgrade five of the most widely used -- but highly toxic -- anti-cancer drugs. For each of these agents, clinicians would welcome an improvement in their therapeutic efficacy. Equally or more beneficial would be an effort to substantially decrease their well-documented toxicity.

Beside causing severe discomfort and a sharp decline in quality of life, these drugs may induce severe blood toxicity, gastrointestinal hemorrhage or, in rare cases, death.

Drugs currently selected by Pro-Pharmaceuticals for upgrade are among the most commonly prescribed and carry some of the poorest safety profiles:

• 5-Fluorouracil
  
• Adriamyicin
• Taxol
  
• Cytoxan
  
• Cisplatin

As we build our portfolio, we will add other drug candidates.